<DOC>
	<DOC>NCT00569894</DOC>
	<brief_summary>To assess the safety of FluMist vaccination</brief_summary>
	<brief_title>A Post Marking Study to Evaluate the Safety of FluMist in Children</brief_title>
	<detailed_description>- To assess the safety of FluMist vaccination Rates of medically attended events in FluMist recipients, including serious adverse events (SAEs), anaphylaxis , urticaria, asthma, wheezing, pre-specified grouped diagnoses, and rare events potentially related to wild-type influenza, will be compared to rates in multiple non-randomized control groups. - To assess the safety of annual FluMist re-vaccination [Rates of MAEs in the subset of children who receive FluMist in â‰¥2 consecutive years will be compared to rates in first-time vaccinees during the same season.] - To assess the safety of FluMist vaccination in children previously vaccinated with trivalent inactivated influenza vaccine (TIV) [Rates of MAEs in the subset of children who received one or more prior TIV vaccinations will be compared to rates in children who did not receive prior TIV.]</detailed_description>
	<criteria>Healthy Age: born within the same calendar quarter as the reference FluMist vaccinee. Children who have evidence of medical conditions that put them at high risk for complications of influenza (e.g., chronic cardiovascular and pulmonary disease) will be excluded from this control group.</criteria>
	<gender>All</gender>
	<minimum_age>24 Months</minimum_age>
	<maximum_age>59 Months</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>